×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CSLLY – csl ltd sp/adr (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CSLLY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/21
07:18 am
cslly
CSL Limited: Divergent Outlook For Its 2 Key Businesses [Seeking Alpha]
Low
Report
CSL Limited: Divergent Outlook For Its 2 Key Businesses [Seeking Alpha]
2/20
09:31 am
cslly
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) [Yahoo! Finance]
Low
Report
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) [Yahoo! Finance]
2/20
09:13 am
cslly
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
Low
Report
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
2/13
07:07 am
cslly
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) [Yahoo! Finance]
Low
Report
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) [Yahoo! Finance]
2/13
07:00 am
cslly
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
Low
Report
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
2/11
09:18 am
cslly
CSL Limited 2025 Q2 - Results - Earnings Call Presentation [Seeking Alpha]
Medium
Report
CSL Limited 2025 Q2 - Results - Earnings Call Presentation [Seeking Alpha]
2/7
10:09 am
cslly
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B [Yahoo! Finance]
Low
Report
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B [Yahoo! Finance]
1/18
06:14 am
cslly
CSL Limited (OTCMKTS: CSLLY) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Low
Report
CSL Limited (OTCMKTS: CSLLY) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at Jefferies Financial Group Inc from a "hold" rating to a "buy" rating.
22.0%
3/9 Australian shares dip into bear market territory [Reuters] 7.0%
4/8 Australia's CSL stands by profit guidance due to strong demand for blood products [Reuters] 6.4%
4/2 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 5.5%
4/27 Australian shares close higher on global stimulus hopes [Reuters] 3.7%
8/13 Australia shares join global rally as miners bounce, CSL gains [Reuters] 3.5%
2/18 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. 3.3%
1/10 Researchers decipher a new way that immune cells detect infections and cancers 2.9%
1/27 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.8%
10/14 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.5%
3/9 Australian shares dip into bear market territory [Reuters] 7.0%
4/8 Australia's CSL stands by profit guidance due to strong demand for blood products [Reuters] 6.4%
4/2 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 5.5%
4/27 Australian shares close higher on global stimulus hopes [Reuters] 3.7%
8/13 Australia shares join global rally as miners bounce, CSL gains [Reuters] 3.5%
2/18 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. 3.3%
1/10 Researchers decipher a new way that immune cells detect infections and cancers 2.9%
1/27 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.8%
10/14 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.5%
TOP News Decliners
2/24
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
-5.5%
4/21 CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI) -4.1%
12/9 HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -1.4%
11/15 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -1.2%
10/7 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.8%
2/17 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $124.00 price target on the stock. -0.7%
9/4 Australian shares end lower on global growth worries, but NZ rises [Reuters] -0.3%
7/1 CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019 -0.3%
4/9 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $110.00 price target on the stock. -0.3%
1/21 Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity -0.2%
4/21 CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI) -4.1%
12/9 HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -1.4%
11/15 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -1.2%
10/7 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.8%
2/17 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $124.00 price target on the stock. -0.7%
9/4 Australian shares end lower on global growth worries, but NZ rises [Reuters] -0.3%
7/1 CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019 -0.3%
4/9 Commonwealth Bank of Australia (OTCMKTS: CSLLY) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $110.00 price target on the stock. -0.3%
1/21 Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity -0.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: